Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with R-DHAOx or R-GDP in Relapsed/Refractory B-cell Lymphoma
NCT02741388Phase 1Completed
- Sponsor
- LYSARC
- Start
- Oct 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of selinexor in B cell lymphoma (2 arms), sponsored by LYSARC. Primary endpoint: Incidence rate of dose-limiting toxicities at 35 days. Started Oct 2016; status: completed.
02
Drugs
selinexor
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT02741388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02741388.